Holen Sie sich die Stockscreener-App
155.29
2.18%
3.34
Schlusskurs vom Vortag:
$151.95
Offen:
$155.49
24-Stunden-Volumen:
578.66K
Relative Volume:
0.36
Marktkapitalisierung:
$21.49B
Einnahmen:
$1.53B
Nettoeinkommen (Verlust:
$-214.69M
KGV:
-88.23
EPS:
-1.76
Netto-Cashflow:
$-43.68M
1W Leistung:
-1.34%
1M Leistung:
+4.88%
6M Leistung:
+14.91%
1J Leistung:
+47.47%
1-Tages-Spanne:
$154.87
$160.66
1-Wochen-Bereich:
$147.63
$166.00
52-Wochen-Spanne:
$92.14
$183.00
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Vergleichen Sie NTRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
155.29 | 21.49B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
421.38 | 159.40B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
195.26 | 141.27B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
501.84 | 38.21B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
112.94 | 30.90B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
152.11 | 26.35B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera price target raised to $195 from $190 at BTIG - MSN
Natera raises 2025 revenue outlook to $1.94B-$2.02B with 26% growth target - MSN
Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
UBS Raises Natera (NTRA) Price Target to $218, Maintains Buy Rat - GuruFocus
Natera First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Natera, Inc. (NASDAQ:NTRA) Q1 2025 Earnings Call Transcript - Insider Monkey
NTRA Price Target Increased as Natera Achieves Record Growth | N - GuruFocus
NTRA: Barclays Raises Price Target for Natera | NTRA Stock News - GuruFocus
Natera’s Strong Performance and Growth Potential Justifies Buy Rating - TipRanks
Natera Inc. Shines in Earnings Call with Strong Growth - TipRanks
Cathie Wood’s ARK buys Shopify, Illumina stock; sells Palantir, Natera - Investing.com
Natera Shares Dip Amid Profitability Concerns - TipRanks
RBC maintains Outperform on Natera stock, price target at $251 - Investing.com
Natera stock price target raised to $200 at TD Cowen - Investing.com
RBC maintains Outperform on Natera stock, price target at $251 By Investing.com - Investing.com India
NTRA: TD Cowen Increases Price Target on Strong Performance | NT - GuruFocus
NTRA Reports Strong Q1 Revenue Exceeding Expectations | NTRA Sto - GuruFocus
NTRA: TD Cowen Increases Price Target on Strong Performance | NTRA Stock News - GuruFocus
8 Analysts Have This To Say About Natera - Benzinga
NTRA Price Target Increased as Natera Achieves Record Growth | NTRA Stock News - GuruFocus
NTRA Stock Sees Price Target Increase by Barclays to $190 | NTRA Stock News - GuruFocus
Natera Q1 2025 slides: 37% revenue growth drives raised guidance By Investing.com - Investing.com Nigeria
Natera, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Natera Inc (NTRA) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Raised Guidance - Yahoo Finance
Natera Inc. Reports Strong Q1 2025 Financial Growth - TipRanks
Natera Inc earnings beat by $0.14, revenue topped estimates - Investing.com
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Natera (NTRA) Reports Strong Q1 2025 Growth and Raises Revenue Guidance - GuruFocus
Natera Q1 2025 Earnings Call Transcript - MarketBeat
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales - Yahoo Finance
Earnings call transcript: Natera Q1 2025 beats EPS forecast, stock rises - Investing.com UK
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Natera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NTRA Reports Strong Q1 Revenue Exceeding Expectations | NTRA Stock News - GuruFocus
Natera Q1 2025 slides: 37% revenue growth drives raised guidance - Investing.com
Natera Q1 Net Loss Narrows, Revenue Rises; Increases Full Year Revenue Outlook - marketscreener.com
Natera: Q1 Earnings Snapshot - marketscreener.com
Natera Inc (NTRA) Q1 2025 Earnings: EPS of ($0.50) Beats Estimate, Revenue Surges to $501.8 Million, Exceeding Expectations - GuruFocus
Earnings Flash (NTRA) NATERA INC. Reports Q1 Revenue $501.8M, vs. FactSet Est of $446.2M - marketscreener.com
Natera Reports First Quarter 2025 Financial Results - Yahoo Finance
Natera (NTRA) to Present Significant Breast Cancer Data at 2025 ESMO Congress | NTRA Stock News - GuruFocus
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress | NTRA Stock News - GuruFocus
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress - Yahoo Finance
Natera Inc (NTRA) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Cathie Wood’s ARK Makes Bold Tuesday Moves with Key Stock Swaps - Wall Street Pit
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows - BioSpace
What To Expect From Natera’s (NTRA) Q1 Earnings - Yahoo Finance
Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas - Medical Device Network
Natera (NTRA) Highlights Promising Study Results for Sarcoma Det - GuruFocus
Natera (NTRA) Highlights Promising Study Results for Sarcoma Detection | NTRA Stock News - GuruFocus
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera | NTRA Stock News - GuruFocus
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Natera Inc-Aktie (NTRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
May 01 '25 |
Sale |
150.12 |
3,000 |
450,353 |
136,205 |
| Marcus Gail Boxer | Director |
May 01 '25 |
Option Exercise |
24.42 |
4,000 |
97,680 |
13,704 |
| Marcus Gail Boxer | Director |
May 01 '25 |
Sale |
151.61 |
4,000 |
606,433 |
9,704 |
0.06%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):